New combo therapy aims to control advanced breast cancer after other treatments fail
NCT ID NCT05530057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a trastuzumab biosimilar (SB3) to the chemotherapy drug eribulin helps control advanced HER2-positive breast cancer better than eribulin alone. It includes 180 adults whose cancer has spread or cannot be removed and who have already tried at least two prior HER2-targeted treatments. The main goal is to see how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Could immune activators revive treatment for Hard-to-Treat breast cancer?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- New drug sequence aims to outsmart advanced breast cancer